Monopar Therapeutics (NASDAQ:MNPR) Issues Earnings Results

Monopar Therapeutics (NASDAQ:MNPR) released its quarterly earnings results on Monday. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87), Zacks reports.

Monopar Therapeutics Stock Down 8.2 %

NASDAQ:MNPR traded down $2.98 on Tuesday, reaching $33.43. The company’s stock had a trading volume of 36,886 shares, compared to its average volume of 357,146. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The stock has a 50 day moving average price of $38.48 and a 200 day moving average price of $24.33. The firm has a market cap of $203.99 million, a price-to-earnings ratio of -16.97 and a beta of 1.18.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Piper Sandler reiterated an “overweight” rating and set a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Monopar Therapeutics in a research note on Tuesday.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.